Trial Search Results

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective when given alone or together with cetuximab in treating patients with head and neck cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for locally advanced head and neck cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Radiation Therapy Oncology Group

Collaborator: NRG Oncology


  • Biological: cetuximab
  • Radiation: intensity-modulated radiation therapy


Phase 3



   - Histologically confirmed squamous cell carcinoma (including variants, such as
   verrucous carcinoma, spindle cell carcinoma, or carcinoma not otherwise specified) of
   the head and neck, including the following subtypes:

      - Oral cavity

      - Oropharynx

      - Larynx

   - Clinical stage T1, N1-2, M0 OR T2-4a, N0-2, M0 disease based on the following
   diagnostic workup within the past 8 weeks:

      - General history and physical examination by a Radiation Oncologist and/or Medical

      - Chest x-ray or chest CT scan (with or without contrast) or chest CT/PET scan
      (with or without contrast)

   - Must have undergone gross total resection of the primary tumor with curative intent
   within the past 7 weeks with surgical pathology demonstrating ≥ 1 of the following
   criteria for "intermediate" risk of recurrence:

      - Perineural invasion

      - Lymphovascular invasion

      - Single lymph node > 3 cm or ≥ 2 lymph nodes (all < 6 cm) (no extracapsular

      - Close margin(s) of resection, defined as cancer extending to within 5 mm of a
      surgical margin, and/or an initially focally positive margin that is subsequently
      superseded by intraoperative negative margins (similarly, patients whose tumors
      had focally positive margins in the main specimen but negative margins from
      re-excised samples in the region of the positive margin are eligible)

      - Pathologically confirmed T3 or T4a primary tumor

      - T2 oral cavity cancer with > 5 mm depth of invasion

   - No positive margin(s) (defined as tumor present at the cut or inked edge of the
   tumor), nodal extracapsular extension, and/or gross residual disease after surgery


   - Zubrod performance status 0-1

   - Absolute granulocyte count ≥ 1,500/mm³

   - Platelet count ≥ 100,000/mm³

   - Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention allowed)

   - Total bilirubin < 2 times upper limit of normal (ULN)

   - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN

   - Serum creatinine < 2 times ULN OR creatinine clearance ≥ 50 mL/min

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

   - No other invasive malignancy within the past 3 years, except for nonmelanomatous skin
   cancer or previously treated carcinoma in situ of the breast, oral cavity, or cervix

   - No simultaneous primary or bilateral tumors

   - No severe, active co-morbidity, including any of the following:

      - Unstable angina and/or congestive heart failure requiring hospitalization within
      the past 6 months

      - Transmural myocardial infarction within the past 6 months

      - Acute bacterial or fungal infection requiring IV antibiotics at the time of study

      - Chronic obstructive pulmonary disease exacerbation or other respiratory illness
      requiring hospitalization or precluding study therapy

      - Idiopathic pulmonary fibrosis or other severe interstitial lung disease that
      requires oxygen therapy or is thought to have required oxygen therapy within the
      past year

      - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

      - AIDS based on current Centers for Disease Control (CDC) definition

      - Grade 3-4 electrolyte abnormalities according to CTCAE, v. 4, including any of
      the following:

         - Serum calcium (ionized or adjusted for albumin) < 7 mg/dL or > 12.5 mg/dL*

         - Glucose < 40 mg/dL or > 250 mg/dL

         - Magnesium < 0.9 mg/dL or > 3 mg/dL*

         - Potassium < 3.0 mmol/L or > 6 mmol/L*

         - Sodium < 130 mmol/L or > 155 mmol/L* NOTE: *Despite intervention to
         normalize levels.

   - No prior allergic reaction to cetuximab


   - See Disease Characteristics

   - No prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for this

      - Prior chemotherapy or anti-EGF therapy for a different cancer allowed

   - No prior radiotherapy to the region of the study cancer that would result in overlap
   of radiotherapy fields

   - No concurrent amifostine as a radioprotector

   - No concurrent granulocyte colony-stimulating factor or erythropoietin

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting